Shanghai Haoyuan Chemexpress Co. Ltd. A Asset Resilience Ratio
Shanghai Haoyuan Chemexpress Co. Ltd. A asset resilience ratio. Shanghai Haoyuan Chemexpress Co. Ltd. A (688131) has an Asset Resilience Ratio of 1.37% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Shanghai Haoyuan Chemexpress Co. Ltd. A to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Shanghai Haoyuan Chemexpress Co. Ltd. A (2022–2025)
Asset resilience ratio of Shanghai Haoyuan Chemexpress Co. Ltd. A from 2022 to 2025. This chart shows how Shanghai Haoyuan Chemexpress Co. Ltd. A's Asset Resilience Ratio has changed over time. Read Shanghai Haoyuan Chemexpress Co. Ltd. A (688131) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Shanghai Haoyuan Chemexpress Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Shanghai Haoyuan Chemexpress Co. Ltd. A balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥89.00 Million | 1.37% |
| Total Liquid Assets | CN¥89.00 Million | 1.37% |
Asset Resilience Insights
- Limited Liquidity: Shanghai Haoyuan Chemexpress Co. Ltd. A maintains only 1.37% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shanghai Haoyuan Chemexpress Co. Ltd. A Industry Peers by Asset Resilience Ratio
Compare Shanghai Haoyuan Chemexpress Co. Ltd. A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Porton Fine Chemicals Ltd
SHE:300363 |
Drug Manufacturers - Specialty & Generic | 6.85% |
|
Jubilant Pharmova Limited
NSE:JUBLPHARMA |
Drug Manufacturers - Specialty & Generic | 1.26% |
Shanghai Haoyuan Chemexpress Co. Ltd. A Asset Resilience Ratio by Year (2022–2025)
Shanghai Haoyuan Chemexpress Co. Ltd. A asset resilience ratio by year from 2022 to 2025. The table below shows the annual Asset Resilience Ratio data for Shanghai Haoyuan Chemexpress Co. Ltd. A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.32% | CN¥20.07 Million ≈ $2.94 Million |
CN¥6.29 Billion ≈ $921.05 Million |
-7.84pp |
| 2024-12-31 | 8.16% | CN¥449.15 Million ≈ $65.72 Million |
CN¥5.50 Billion ≈ $805.55 Million |
+7.68pp |
| 2022-12-31 | 0.48% | CN¥17.23 Million ≈ $2.52 Million |
CN¥3.60 Billion ≈ $526.46 Million |
-- |
About Shanghai Haoyuan Chemexpress Co. Ltd. A
Shanghai Haoyuan Chemexpress Co., Ltd. researches, develops, and manufactures pharmaceutical intermediates and small molecule drugs. The company offers APIs and API intermediates, vitamin D series compounds, CRO building blocks, and CRO life bioscience compounds. The company was founded in 2006 and is headquartered in Shanghai, China.